Product Information
ALOGLIPTIN-METFORMIN 12.5-1000 is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $2.4649 per EA under NDC 45802021172. Its NADAC has been published 533 times since Jul 20, 2016.
FDA first approved this application on Jan 25, 2013.
Strength
12.5; 1000 mg/1; mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802021172
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA203414FDA Approved
1/25/2013
On Market Since
4/8/2016
Pharmacological Classes
Price Statistics
The NADAC for ALOGLIPTIN-METFORMIN 12.5-1000 has been published 533 times since Jul 20, 2016, and over the history we have for it it has declined 31.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.4649 per EA |
|---|---|
| All-time high | $3.5922 (Mar 15, 2017) |
| All-time low | $2.2473 (Oct 18, 2023) |
| 52-week high | $2.5444 |
| 52-week low | $2.2683 |
| Median price | $2.6662 |
| Average price | $2.6890 |
| Largest weekly change | +27.6% (Nov 22, 2023) |
| Weeks tracked | 533 |
| Tracking since | Jul 20, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
alogliptin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALOGLIPTIN-METFORMIN 12.5-1000?
The current National Average Drug Acquisition Cost (NADAC) for ALOGLIPTIN-METFORMIN 12.5-1000, manufactured by Padagis Israel Pharmaceuticals Ltd, is $2.4649 per EA (NDC 45802021172), effective Sep 30, 2026.
How has the price of ALOGLIPTIN-METFORMIN 12.5-1000 changed over time?
Over the history we have for it, the NADAC for ALOGLIPTIN-METFORMIN 12.5-1000 has declined 31.4%. It has been tracked across 533 weekly CMS publications since Jul 20, 2016.
What are the highest and lowest recorded NADAC prices for ALOGLIPTIN-METFORMIN 12.5-1000?
Since Jul 20, 2016, the NADAC for ALOGLIPTIN-METFORMIN 12.5-1000 has ranged from a low of $2.2473 (Oct 18, 2023) to a high of $3.5922 (Mar 15, 2017), with a median of $2.6662 per EA.
Are there cheaper alternatives to ALOGLIPTIN-METFORMIN 12.5-1000?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ALOGLIPTIN-METFORMIN 12.5-1000 in a comparable dosage form, but none are currently priced below it.
Who manufactures ALOGLIPTIN-METFORMIN 12.5-1000?
ALOGLIPTIN-METFORMIN 12.5-1000 (NDC 45802021172) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.